Abstract Purpose: The germ-line polymorphisms TP53 Arg72Pro and MDM2 SNP309 T>G are risk factors for tumor development and affect response to chemotherapy and survival in several cancers, but their prognostic and predictive value in patients with high-grade osteosarcomas is not yet defined. The purpose of this study was to investigate the effect of the TP53 Arg72Pro and the MDM2 SNP309 on the risk of osteosarcoma development and survival. Experimental Design: The relative risk to develop osteosarcomas and the overall survival associated to TP53 Arg72Pro and MDM2 SNP309 polymorphisms were investigated in 201 patients. Correlations with event-free survival (EFS) were analyzed in a homogeneous subgroup of 130 patients with high-grade osteosarcomas of the limbs, nonmetastatic at diagnosis, which underwent neoadjuvant chemotherapy. Results: Multivariate analysis showed that the MDM2 polymorphism T309G was associated with an increased risk of developing osteosarcomas [GG versus TT; odds ratio, 2.09; 95% confidence interval (95% CI), 1.15-3.78]. A case/control gender approach evidenced a significant increased risk only for female osteosarcoma patients (GG versus TT; odds ratio, 4.26; 95% CI, 1.61-11.25). Subjects carrying the TP53 Arg72Pro polymorphism were found to have a significantly increased death risk (Pro/Pro versus Arg/Arg; hazard ratio, 2.90; 95% CI, 1.28-6.66). In the subgroup of 130 high-grade osteosarcomas, the TP53 Arg72Pro was an independent marker of EFS (Pro/Pro versus Arg/ Arg; hazard ratio, 2.67; 95% CI, 1.17-6.11).
The products of TP53 and MDM2 oncosuppressive genes are related with a feedback loop for regulating localization and activation of TP53 downstream signal. MDM2 gene codes for a protein that binds TP53 and inhibits its transcriptional activity (1) .
TP53 shows frequent somatic mutations in human cancers and is commonly associated with a more aggressive tumor phenotype, with worse clinical outcome (2) (3) (4) and with an increased risk for developing cancers (5) (6) (7) . Positive correlations between TP53 status and response to chemotherapy or disease progression have been reported in osteosarcomas or soft tissue sarcomas (STS) but with contradictory evidence (8) (9) (10) (11) . A meta-analysis of 16 studies in human osteosarcomas evaluating the correlation between TP53 protein expression in tumor cells, histologic response to chemotherapy, and 2-year survival failed to find a relationship, whereas the TP53 gene mutations were found to be variably associated with decreased survival (12) .
A common polymorphism of TP53 is located at codon 72 of the exon 4 leading to an amino acid change (Arg72Pro, rs1042522). The presence of this genetic polymorphism brings to the loss of one of the five PXXP repeats (P represents Pro and X represents any amino acid) altering the protein structure and decreasing induction of apoptosis (13) . Patients with the Pro allele seem to have a poor prognosis and survival in different tumors, such as breast (14, 15) , ovarian (16) , lung (15) , head and neck cancer (15) , and esophageal squamous cell carcinoma (17) . However, these correlations are not unequivocal (7, 18) .
In humans, MDM2 was shown to be overexpressed in a subset of tumors. This overexpression is frequently associated with an accelerated cancer progression and lack of response to therapy (19, 20) . Amplification and overexpression of MDM2 in human sarcomas (21) (22) (23) can stimulate cell proliferation, enhance cell survival, and induce resistance to conventional chemotherapy.
A common polymorphism of MDM2 gene occurs at the nucleotide 309 and determines the substitution of T with G (rs2279744). This polymorphism, which involves the second MDM2 promoter-enhancer region, extends the length of Sp1 binding site, increasing the MDM2 basal level. This effect attenuates the increase of TP53 protein levels, with a consequent decrease of the TP53 apoptotic response, leading to a faster and more frequent tumor formation (24) (25) (26) (27) (28) . The effect of 309G allele on the age of tumor onset seems to be gender specific, decreasing the age of cancer diagnosis in women but not in men affected by STS, B-cell lymphoma (26) , and breast cancer (29) . These results could be explained by the location of SNP309 in a region that is regulated by estrogen signaling (30, 31) .
The aim of this study was to investigate the association of the TP53 Arg72Pro and the MDM2 T309G on the risk of high-grade osteosarcoma development and their effect on survival. Moreover, this work was done to evaluate the effect of these polymorphisms on development of STS.
Materials and Methods
Patients. The study included 201 Caucasian patients with high-grade osteosarcomas from the Istituto Ortopedico Rizzoli (Bologna, Italy) and from the Centro di Riferimento Oncologico-National Cancer Institute (Aviano, Italy) collected between March 1992 and December 2004. DNA was isolated from frozen normal muscular tissues of diagnostic biopsy or peripheral blood collected at the time of the first operation. Cases had conventional histopathologic parameter analysis, including stage (tumor-node-metastasis), tumor type, and grade of differentiation, defined following the WHO guidelines (32) . All these patients were checked on a regular follow-up basis (median, 41 mo; range, 1-180) from the time of diagnosis or until death. Overall survival was calculated from the time of diagnosis until death or last follow-up.
Among the 201 osteosarcomas, a homogeneous subgroup of 130 patients was considered to be eligible for event-free survival (EFS) analyses. These 130 cases included patients newly diagnosed for high-grade intramedullary osteosarcomas of the limbs without prior treatment and with no evidence of metastasis at diagnosis. All these cases were treated with neoadjuvant chemotherapy protocols (based on doxorubicin, high-dose methotrexate, cisplatin, and ifosfamide) and surgery (33) . EFS was calculated from the first day of preoperative chemotherapy to the most recent follow-up examination, local or systemic recurrence, or death unrelated to the tumor (33) .
Two hundred and fifty healthy Caucasian control subjects were randomly selected from a pool of healthy volunteers (age range, 18-40 y), who had signed the informed consent to use their biological material for genetic analysis. The study was approved by both the local ethics committees.
Additional 129 STS patients from Centro di Riferimento Oncologico were also included in the study to investigate the effect of the TP53 Arg72Pro and the MDM2 SNP309 on STS risk of development. Genotyping assays. Genotyping analyses of TP53 and MDM2 genes were done after DNA extraction by High Pure PCR Template Preparation kit (Roche Diagnostic GmbH) using Pyrosequencing technology with specific 5′-biotinylated primers.
For TP53 analysis, we used a 50 μL volume reaction containing 2. . Sequencing primers (TP53-CA-GAGGCTGCTCCCC and MDM2-GGGCTGCGGGGCCGCT) were developed using SNP Primer Design software (version 1.0) from Biotage AB. Genotyping was done using a PSQ96 pyrosequencer according to the manufacturer's instructions. Samples that were difficult to interpret because of an unclear heterozygous status for Arg72Pro polymorphism were confirmed with a validated Taqman assay.
Statistical analysis. The distribution of individual characteristics was assessed by simple descriptive statistics. Differences among distributions of selected variables were evaluated by using Fisher's exact test for categorical data. The Hardy-Weinberg equilibrium assumption was assessed by the standard method of matching the observed numbers of individuals in the different genotype categories with those expected under Hardy-Weinberg equilibrium for the estimated allele frequency and comparing the Pearson goodness-of-fit statistic with the χ 2 distribution with 1 degree of freedom. Genotype distributions were compared with the use of contingency table analysis.
Odds ratio (OR) and corresponding 95% confidence intervals (95% CI) were computed by multiple logistic regression models using as dependent variable case/control status. Overall survival was estimated using the Kaplan-Meier product limit method. Cumulative survival probability was calculated at 60 mo within each of the three genotypes. Differences were tested using the log-rank test. To assess the relative excess risk of relapse/death in patients with different genotypes and to control for confounding factors, proportional hazards models (including sex, age, primary sites, and neoadjuvant chemotherapy) were fitted computing hazard ratios (HR) and the corresponding 95% CIs.
Translational Relevance
The study analyzes the role of two common polymorphisms, the TP53 Arg72Pro and the MDM2 SNP309 T>G, on the risk of developing high-grade osteosarcomas and their effect on overall survival and event-free survival after neoadjuvant treatment. The prognostic and predictive value of TP53 Arg72-Pro and the MDM2 SNP309 T>G in cancer patients is an emerging issue, but at present, inconsistent data have been reported for osteosarcomas. Our study provides evidence supporting the association of MDM2 SNP309 T>G with high-grade osteosarcoma risk in females [GG versus TT; odds ratio, 4.26; 95% confidence interval (95% CI), 1.61-11.25] and shows that TP53 Arg72Pro had a prognostic value for overall survival (Pro/Pro versus Arg/Arg; hazard ratio, 2.90; 95% CI, 1.28-6.66) and event-free survival (hazard ratio, 2.67; 95% CI, 1.17-6.11, compared with Arg/ Arg) after neoadjuvant treatment of osteosarcoma patients. This could lead to consideration of this genetic variant as a possible new candidate prognostic marker for high-grade osteosarcomas.
The proportional assumption was examined with log-log survival plots or by adding time-dependent interaction terms to the model.
Results
MDM2 SNP309 and TP53 Arg72Pro distribution and relative risk of osteosarcoma and STS development.Clinicopathologic features of the patients for the entire group of 201 cases are reported in Table 1 . The median age of the whole group of 201 osteosarcoma patients (123 males and 78 females) was 16 years (range, 4-73).
The frequencies of MDM2 and TP53 genotype among cases and controls are shown in Table 2 . In the 201 osteosarcoma patients, the MDM2 SNP309 polymorphism frequencies were as follows: TT, 34.3%; TG, 42.8%; and GG, 22.9%. The frequencies of MDM2 SNP309 among controls were as follows: TT, 44.4%; TG, 42.8%; and GG, 12.8%. A borderline deviation from the Hardy-Weinberg equilibrium was only observed among cases (P = 0.06).
The MDM2 T309G polymorphism was significantly associated with an increased risk for developing osteosarcomas. The prevalence of the MDM2 GG genotype among the 201 cases (46 of 201, 22.9%) was significantly higher than in controls (32 of 250, 12.8%; P = 0.003). The ORs associated with MDM2 SNP309 GT heterozygotes and GG homozygotes compared with wild-type TT homozygotes were 1.21 (95% CI, 0.77-1.90) and 2.09 (95% CI, 1.15-3.78), respectively.
A stratification by gender highlighted a significant association between the MDM2 GG genotype and the relative risk to develop osteosarcomas among females, but not among males. As shown in Table 3 , case/control analysis in the female subgroup showed that subjects carrying the GG genotype presented an ∼4-fold higher risk (OR, 4.26; 95% CI, 1.61-11.25) to develop osteosarcomas compared with females carrying the TT genotype, whereas the relative risk in males was 1.39 (95% CI, 0.64-3.03). Moreover, the osteosarcoma relative risk among females carrying at least one G allele (TG + GG) was significantly increased ∼2-fold (OR, 1.96; 95% CI, 1.04-3.67) compared with males carrying the G allele (TG + GG).
As shown in Table 2 , the frequencies of TP53 genotypes in the 201 osteosarcomas were 70.6% (Arg/Arg), 21.4% (Arg/ Pro), and 8.0% (Pro/Pro), whereas in controls they were 58.4%, 34.8%, and 6.8%, respectively.
There was no evidence for deviation from the HardyWeinberg equilibrium among controls, whereas a significant difference was observed for TP53 Arg72Pro among cases (P = 0.0001). No increased risk to develop osteosarcomas was observed in association with the Pro/Pro genotype variant. On the contrary, we noted even a reduced risk for the heterozygous Arg/Pro compared with Arg/Arg (OR, 0.48; 95% CI, 0.30-0.77).
Both TP53 Arg72Pro and MDM2 SNP309 polymorphisms were not significantly associated with the most relevant clinicopathologic features of the 201 osteosarcoma patients: histologic grade, stage, site (extremities versus other sites), histotype (osteoblastic versus others), and extent of tumor necrosis (good ≥90% versus poor <90%) after preoperative chemotherapy (data not shown).
Several studies have indicated that MDM2 and TP53 also have a role in STS (8, 21, 22, 26) . On these assumptions, we investigated the MDM2 SNP309 and TP53 Arg72Pro on STS risk in 129 patients (see Materials and Methods). A similar result to those observed in osteosarcomas was evidenced also in STS for both polymorphisms. The ORs associated with MDM2 SNP309 GT heterozygotes and GG homozygotes, compared with wild-type TT homozygotes, were 1.34 (95% CI, 0.84-2.14) and 2.67 (95% CI, 1.48-4.83), respectively. About TP53 Arg72Pro, no significant differences were observed between wild-type Arg/Arg and mutated Pro/Pro (OR, 0.97; 95% CI, 0.45-2.10). Nevertheless, heterozygous Arg/Pro compared with wild-type Arg/Arg had a significant reduced risk for developing STS (OR, 0.46; 95% CI, 0.27-0.77).
Correlation with relapse rate and survival of TP53 Arg72Pro and MDM2 SNP309 polymorphisms in osteosarcomas. Among the 201 osteosarcomas investigated, the most relevant predictors for the overall survival selected by the stepwise procedure using a Cox model were the stage at diagnosis and the TP53 Arg72Pro polymorphism. In particular, the risk for death in comparison with that of the wild-type Arg/Arg genotype was, respectively, 1.30 (95% CI, 0.66-1.57) for the Arg/Pro and (Table 4) . Further analyses on the association between clinical outcome and polymorphisms were carried out on the subgroup of 130 high-grade, nonmetastatic osteosarcomas of the extremities in patients who were homogeneously treated with neoadjuvant chemotherapy and surgery (Table 1) . Adverse events (7 local recurrences, 47 lung metastasis, and 3 deaths for disease) occurred in 57 patients (44.0%). In this subgroup of patients, TP53 Pro/Pro genotype emerged as an adverse prognostic factor for EFS (Fig. 1) . Compared with the wild-type Arg/Arg genotype, the HRs were 1.83 (95% CI, 1.04-3.25) and 2.67 (95% CI, 1.17-6.11) for heterozygous Arg/Pro and homozygous Pro/Pro, respectively (Table 5) . On the contrary, no significant associations between MDM2 SNP309 polymorphism and overall survival or EFS were observed in the 130 homogenously treated osteosarcomas (Table 5 ) or in the entire group of 201 osteosarcoma patients (Table 4) .
Discussion
This study focused on the evaluation of polymorphisms affecting the TP53 and MDM2 genes in relation to pathogenesis and tumor progression of high-grade osteosarcomas and STS. The MDM2 309 G>T germ-line polymorphism has been associated with an increased risk of tumor formation in humans, including adult STS patients (26) . The present study supports an involvement of the MDM2 T309G SNP in STS cancer risk and firstly showed that this polymorphism is implicated also in the development of high-grade osteosarcomas. The risk to develop osteosarcomas was increased ∼2-fold (OR, 2.09; 95% CI, 1.15-3.78) in patients with the SNP309 GG genotype compared with the wild-type TT genotype.
A moderate statistical power affects the results of our study. In fact, post hoc estimated power for MDM2 SNP309 T>G polymorphism for an unmatched case-control approach was 0.56, but osteosarcoma occurrence in population is a rare event. In Italy, the overall incidence rate of bone neoplasm is <1 new case for 100,000 persons/year and osteosarcoma/Ewing sarcoma morphologies represent <30% of all bone tumors (34) .
We observed a gender-specific difference in the osteosarcoma risk related to SNP309 (26) . Case/control matching by gender evidenced a significant difference only for females (OR, 4.26; 95% CI, 1.61-11.25) but not for males (OR, 1.39; 95% CI, 0.64-3.03). Many reports have shown that MDM2 mRNA and protein levels are heightened in breast tumors, which express the estrogen receptor (30, 35) : the regulation of MDM2 expression by estrogen is mediated through a promoter site adjacent to SNP309. These data support the hypothesis that genderspecific hormones, such as estrogen, could be playing a role in the ability of the G allele in osteosarcoma formation in women as observed for STS. Bond et al. (26) reported that in STS female patients, the differences in age-specific cancer incidence between GG and TT were the largest below the average age of menopause when estrogens are at the highest level. As expected, the median age of the osteosarcomas in our study was relatively low (16 years).
Arg72Pro polymorphism in the TP53 gene has been associated with a genetic risk for particular tumor types (14) (15) (16) , but other studies do not support these results (18) . The ambiguous conclusions about the predictive value of the TP53 Arg72Pro polymorphism could be related to the heterogeneousity of the analyzed population, the small sample size, or the ethnic differences in allele frequency. In a preliminary study, Savage et al. (7) provide some suggestions of a possible involvement of the Pro allele in osteosarcomas, but the author recommended further larger case-control analysis for final conclusions. Our work represents the largest series of osteosarcomas in which Arg72Pro polymorphism was evaluated.
Conversely to what was observed in the classic Li-Fraumeni syndrome where the germ-line mutations were a risk for multiple cancer including osteosarcomas (2, 36) , the Pro/Pro genotype in the TP53 gene was not associated with an increased genetic risk factor for sporadic osteosarcomas. We noted even a reduced risk for the subjects harboring the heterozygous genotype Arg/Pro. This latter observation is not surprising because the Arg allele is mainly involved in apoptosis, whereas the Pro allele affects the cell cycle (37, 38) . Probably, the concomitant presence of the two alleles leads to the most protective genotype for osteosarcomas. In the cancer risk study, some bias could derive from selection of the control population. The frequency of the Arg72Pro genotypes in our control subjects was not significantly different than in previous controls in Caucasian populations (39) and that their distribution followed the Hardy-Weinberg equilibrium (16, 40) . Among Caucasians, the Arg72Pro SNP is the most studied among TP53 polymorphisms (14, 16, 18) . Nevertheless, other polymorphisms have been described in the TP53 gene, including a 16-bp duplication in intron 3 (rs1642785) and a common SNP in intron 6 (13494G>A, rs1625895; refs. 41, 42) , which are in a linkage disequilibrium with the codon 72 polymorphism. None of these TP53 polymorphisms or related haplotypes showed any significant association with osteosarcoma risk (data not shown).
In tumor cells, the TP53 status (amplification and overexpression) has been identified as a determinant of chemotherapy response both in vivo and in vitro. This is likely a result of the role of TP53 in cell cycle arrest and apoptosis (3, (43) (44) (45) . In vitro data have also shown that cells with 72Arg allele have an increased sensitivity to chemotherapy secondary to a more vigorous apoptotic response (46, 47) . Data about the effect of TP53 status on response to chemotherapy in osteosarcomas are still controversial. There is a general agreement on the detrimental effect of TP53 status on overall survival (12) . In our study, osteosarcoma patients harboring the Arg allele showed a significantly longer EFS after neoadjuvant chemotherapy and a significant longer overall survival in the entire series of osteosarcomas. The introduction of neoadjuvant chemotherapy has changed the surgical treatment of osteosarcomas reducing limb amputation concomitantly with an improvement of clinical outcome. The critical point, which severely affects the outcome of high-grade osteosarcoma patients after neoadjuvant and surgical treatment, is the occurrence of tumor relapse and metastasis. Thus, it is important to define new predictive markers associated with a higher risk of relapse and with a worse clinical outcome in osteosarcomas. We found that after accounting for clinical factors, the relative risk of relapse was increased 2.6-fold in patients with the TP53 Pro/Pro genotype compared with the wild-type Arg/Arg. EFS is an important predictive indicator for survival in osteosarcomas (48, 49) . In our work, TP53 Arg72Pro polymorphism proved to have a powerful effect for osteosarcoma overall survival as well as for EFS. This could lead to consideration of this genetic variant as a possible new candidate prognostic marker of high-grade osteosarcomas.
In conclusion, the major findings of this study are that germline TP53 codon 72 Pro/Pro genotype has worse survival and worse EFS after neoadjuvant treatment of osteosarcoma patients, whereas MDM2 SNP309 GG genotype is related to an increased risk to develop osteosarcomas among females.
Whether TP53 Arg72Pro and MDM2 SNP309 polymorphisms represent an alternative mechanism for TP53 inactivation resulting in different predictive and prognostic values warrants further prospective studies.
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